UNSPSC 51182705: Metformin/pioglitazone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182705 Metformin/pioglitazone is a Commodity code that shows little relevant recent activity in state and local procurement. The one recent opportunity tagged under this code—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026—does not match the code's nominal scope. Seminole County solicited 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through an IFB with a response deadline of July 26, 2023, a procurement focused on emergency medical supplies and harm-reduction equipment rather than diabetes-management pharmaceuticals. The mismatch between the code classification and the actual goods being procured suggests either a tagging error in the county's e-Procurement Portal or a broader indexing inconsistency; this code does not currently surface actionable state and local demand for metformin or pioglitazone combinations.

The Seminole County solicitation does provide a data point on county health procurement mechanics: the county requires electronic bid submission through its e-Procurement Portal, includes shipping and delivery costs in bid pricing, mandates E-Verify compliance and drug-free workplace certification, and structures contracts with initial two-year terms and one-year renewal options. The procurement included potential FEMA funding with associated federal compliance requirements. Without additional recent opportunities properly classified under this Commodity code, no pattern of geographic concentration, issuing-body type, or market activity emerges to guide pursuit decisions.